A double blind, randomised, placebo controlled trial investigating the efficacy and role of Synbiotic Cocktail 2000 in the treatment of Clostridium difficile diarrhoea and colitis
| ISRCTN | ISRCTN10171652 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10171652 |
| Secondary identifying numbers | N0265122366 |
- Submission date
- 12/09/2003
- Registration date
- 12/09/2003
- Last edited
- 17/04/2015
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr S Pathmakanthan
Scientific
Scientific
GI Medicine
Selly Oak Hospital
Birmingham
B29 6JD
United Kingdom
Study information
| Study design | Double-blind randomised placebo-controlled trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Scientific title | A double blind, randomised, placebo controlled trial investigating the efficacy and role of Synbiotic Cocktail 2000 in the treatment of Clostridium difficile diarrhoea and colitis |
| Study objectives | 1. To assess the role of Synbiotic Cocktail 2000 on symptom duration and relapse rates in patients with one or more episodes of C. difficile diarrhoea 2. To confirm the safety, tolerance and efficacy of Synbiotic Cocktail 2000 used with metronidazole for treatment of C. difficile diarrhoea and colitis compared with metronidazole and placebo 3. To assess the rate of C. difficile toxin and C. difficile elimination with Synbiotic Cocktail 2000 when compared to placebo 4. To investigate the ability of Synbiotic Cocktail 2000 to inhibit C. difficile and Toxin A production in vitro 5. To investigate the efficacy and duration of human gut colonisation by Synbiotic Cocktail 2000 during and after treatment 6. To investigate and characterise mucosa-associated bacteria in patients with antibiotic associated colitis before and after treatment with Synbiotic Cocktail 2000 |
| Ethics approval(s) | Not provided at time of registration |
| Health condition(s) or problem(s) studied | Clostridium difficile diarrhoea and colitis |
| Intervention | Treatment will be initiated at the time of acute relapse and patients will commence on oral metronidazole with either probiotic or placebo. Antibiotic therapy will be continued for seven days while probiotic or placebo will continue for three weeks. Any relapse in symptoms will require oral vancomycin. Stool samples will be obtained daily during initial metronidazole therapy until two stool samples are negative for C. difficile toxin. Daily stool diaries will be kept by all patients. At the end of the three week period of probiotic therapy, patients will undergo a rigid sigmoidoscopy examination and one rectosigmoid biopsy obtained for culture. |
| Intervention type | Other |
| Primary outcome measure | Disease relapse over one month |
| Secondary outcome measures | 1. Disease relapse over three months 2. Rate of loss of C. difficile and toxin from the stool 3. Time to resolution of diarrhoea |
| Overall study start date | 16/01/2003 |
| Completion date | 16/01/2004 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Not Specified |
| Sex | Not Specified |
| Target number of participants | 120 |
| Key inclusion criteria | Any patient with a stool sample positive for Toxin A and clinically symptomatic in the Trust will be offered entry into the trial. ASSESSMENT ON ADMISSION INTO TRIAL: 1. History and physical examination 2. Blood tests 3. Stool analysis for C. difficile and Toxin A 4. Rigid or flexible sigmoidoscopy with biopsies |
| Key exclusion criteria | Patients may be removed from the study if one or more of the following occurs: 1. Protocol violation or non-compliance on part of the patient 2. Refusal of the patient to continue treatment and a decision by the investigator that termination is in the patient's best medical interest (or a significant unrelated medical illness or complication) |
| Date of first enrolment | 16/01/2003 |
| Date of final enrolment | 16/01/2004 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Selly Oak Hospital
Birmingham
B29 6JD
United Kingdom
B29 6JD
United Kingdom
Sponsor information
Department of Health (UK)
Government
Government
Richmond House
79 Whitehall
London
SW1A 2NL
United Kingdom
| Website | http://www.doh.gov.uk |
|---|
Funders
Funder type
Government
University Hospital Birmingham NHS Trust (UK)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
